The 1st EBOVAC2 Newsletter is available!
The 1st EBOVAC2 Newsletter is available!
The first subject was randomized on 10 December 2016 at Makerere University in Uganda.
The first subject was randomized at CHU Treichville in Côte d'Ivoire on 26 February 2016.
The first subject was randomized at the Centre Muraz, Burkina Faso on the 11th of February 2016.
Page 4 of 7
In response to the 2014-2016 Ebola epidemic, the clinical development of a two-dose regimen of...
The 8th EBOVAC2 newsletter is available here. This newsletter announces the European Commission...
Johnson & Johnson announced on 1st July 2020 that the European Commission (EC) has granted...
Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola...
An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the...
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA